Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry)
| Autor: | Timothy D. Henry, Katelyn Storey, Theresa L. Arndt, Christian W. Schmidt, Noel M. Bennett, Jay H. Traverse, Julia Wang, Ross Garberich |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Myocardial Infarction Ranolazine 030204 cardiovascular system & hematology Revascularization Dizziness Drug Costs Angina Pectoris Medication Adherence Angina 03 medical and health sciences Deprescriptions 0302 clinical medicine Refractory Internal medicine Diabetes Mellitus Myocardial Revascularization medicine Edema Humans Registries Treatment Failure 030212 general & internal medicine Myocardial infarction Mortality Aged Dyslipidemias business.industry Smoking Cardiovascular Agents Nausea Canadian Cardiovascular Society Middle Aged medicine.disease Discontinuation Treatment Outcome Tolerability Hypertension Disease Progression Cardiology Female Cardiology and Cardiovascular Medicine business Constipation medicine.drug |
| Zdroj: | The American Journal of Cardiology. 129:1-4 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2020.05.020 |
| Popis: | Ranolazine is approved for patients with chronic stable angina but has not been formally studied in patients with refractory angina pectoris (RAP). Patients with RAP have limited therapeutic options and significant limitations in their quality of life. The Ranolazine Refractory Angina Registry was designed to evaluate the safety, tolerability, and effectiveness of ranolazine in RAP patients in order to expand treatment options for this challenging patient population. Using an extensive prospective database, we enrolled 158 consecutive patients evaluated in a dedicated RAP clinic. Angina class, medications, major adverse cardiac events including death, myocardial infarction, and revascularization were obtained at 12, 24, and 36 months. At 3 years, 95 (60%) patients remained on ranolazine. A ≥2 class improvement in angina was seen in 48% (38 of 80 patients with known Canadian Cardiovascular Society class) of those who remained on ranolazine. Discontinuation due to side effects, ineffectiveness, cost, and progression of disease were the principle reasons for discontinuation, but primarily occurred within the first year. In conclusion, ranolazine is an effective antianginal therapy at 3-year follow-up in patients with RAP and may reduce cardiac readmission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect